Search results
Welcome to the Rockwell Medical Derivative Litigation Website. If you are a holder of Rockwell common stock, your rights may be affected by this Litigation and the proposed Settlement. Important Update: The Settlement Hearing took place on August 10, 2020 at 11:30 a.m., and it was held via telephone conference.
30 wrz 2018 · This Settlement Agreement and Mutual Release (the “Agreement”) is made this 7th day of August, 2018 (the “Execution Date”), by and among Rockwell Medical, Inc. (“Rockwell” or the “Company”), Robert Chioini (“Chioini”), Thomas Klema (“Klema”), Patrick Bagley (“Bagley”), and Ronald Boyd (“Boyd”).
Under the terms of the Stipulation, Rockwell’s board of directors (the “Board”) agrees to implement within ninety (90) days of final settlement approval, and to maintain for a minimum period of four (4) years, the corporate governance reforms described in the Stipulation (the “Reforms”).
7 sie 2018 · The Company will pay the Settling Parties an aggregate payment of $1.5 million, $750,000 of which was paid upon the execution of the Settlement Agreement and nine monthly installments of...
27 lip 2018 · According to the Complaint, Rockwell Medical, Inc. ("Rockwell") operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally.
21 paź 2019 · If you are a member of the Settlement Class, your rights will be affected by the pending Action and the Settlement, and you may be entitled to share in the Settlement Fund.
2 lis 2018 · Rockwell Medical Inc. has hired a new chief financial officer following a whistleblower lawsuit and a $1.5 million settlement with its previous CFO and CEO. The Wixom-based bioscience...
